Revolution Medicines slides as $2.0B upsized offering overhang hits RVMD
Revolution Medicines shares fell as investors digested a freshly completed, upsized $2.0 billion financing that priced at $142 per share and included $500 million of 0.50% convertible notes due 2033. With the stock still near recent highs after a major April clinical catalyst, today’s decline looks driven by post-deal supply and profit-taking pressure.
1) What’s moving the stock today
Revolution Medicines (RVMD) is trading lower as the market continues to absorb its newly completed, upsized capital raise—an overhang that often pressures biotech stocks in the days following pricing and closing. The company priced 10,563,381 shares at $142.00 and issued $500 million of 0.50% convertible senior notes due 2033, creating fresh supply and a new convert arb setup that can weigh on the common stock. (ir.revmed.com)
2) Why the financing matters now
The deal size is large relative to typical biotech issuance and arrived soon after a powerful run-up earlier in April, which can intensify near-term profit-taking. Even when proceeds strengthen the balance sheet, the combination of new shares plus hedging activity tied to the convertible can pressure spot prices until the market finds a clearing level. (ir.revmed.com)
3) What to watch next
Traders will focus on whether RVMD stabilizes above the $142 offering level and whether incremental buyers step in once the post-deal selling and hedging subside. Separately, short positioning remains notable (mid-single-digit to high-single-digit percentage of float depending on the dataset date), which can add volatility if sentiment shifts back toward risk-on biotech. (marketbeat.com)